继续推荐关注创新药及创新产业链 ——医药生物行业2025年7月投资策略 证券研究报告 | 2025年7月17日 行业研究 · 行业投资策略 医药生物 投资评级：优于大市（维持评级） 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈益凌 021-60933167 010-88005445 maqianli@guosen.com.cn S0980521070001 chenyiling@guosen.com.cn S0980519010002 证券分析师：马千里 证券分析师：张超 0755-81982940 zhangchao4@guosen.com.cn S0980522080001 021-60375401 证券分析师：凌珑 证券分析师：肖婧舒 0755-81982826 联系人：贾瑞祥 021-60875137 linglong@guosen.com.cn S0980525070003 xia ...

In its upcoming report, Danaher (DHR) is predicted by Wall Street analysts to post quarterly earnings of $1.64 per share, reflecting a decline of 4.7% compared to the same period last year. Revenues are forecasted to be $5.84 billion, representing a year-over-year increase of 1.6%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this pe ...

中国动物保健市场已经位居全球第二，博杰铭认为未来潜力仍非常大，有更多增长机会。中国的动保市 场相对而言处于发展阶段，需求众多且大多尚未得到充分满足，这无疑是一个巨大的机遇。 挑战与机遇并存 在全球贸易环境日益复杂的背景下，企业也面临诸多挑战。 博杰铭表示，作为一家拥有国际供应链、受益于全球化的企业，关税问题非常重要。"我们正密切关注 相关变化，分地域来进行相关风险的分析，加拿大、墨西哥、欧盟、中国等市场的解决方案各不相 同。" 关税会影响很多宠物主，大多数时候动物保健费用都是由个人支出的，保险的普及率不高，这在预防类 药物特别明显，关税可能带来宠物主支出增加。博杰铭希望可以拓展、加强本土化的生产供应，积极应 对关税带来的挑战。硕腾在中国苏州拥有研发中心和生产基地，为更好地满足本土需求提供了重要支 持。 随着中国年轻消费群体的崛起，宠物经济热潮涌动。 硕腾执行副总裁、首席商务官博杰铭（Jamie Brannan）近日在接受21世纪经济报道记者采访时表示，中 国的宠物市场处在不断上升的周期中，随着市场规模不断扩大，会吸引更多从业者进入这个行业，竞争 日趋加剧，中国市场创新的速度也非常快，需要充分了解中国本土的需求 ...

作为研发驱动型企业，祥生医疗多年来坚持超声医学影像技术国产化战略，现已掌握从二维、三维到四 维超声，从彩超探头核心部件、图像处理算法到整机设计开发，再到临床应用专科化、便携化及人工智 能云平台解决方案的全套核心技术。依托技术积累与市场需求融合，公司在高端化突破的同时，逐步构 建起便携小型化、专科化和智能化的差异化优势。 目前，祥生医疗产品已覆盖国内超过30%的三级医院，广泛应用于超声科、麻醉科、妇产科等众多临床 科室。在国际化布局方面，公司产品已远销全球100多个国家和地区，并与国际知名医疗器械企业建立 了稳固的战略合作关系。 本报讯 （记者李亚男）7月16日晚间，记者从无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"） 获悉，近日，公司全系列全数字彩色超声诊断产品正式通过欧盟医疗器械新规MDR（Medical Devices Regulation，EU2017/745）认证。 据悉，作为取代原有MDD指令（93/42/EEC）的强制性新规，欧盟MDR自2021年5月全面生效，被公认 为国际医疗器械监管最高标准之一。此次通过MDR认证，标志着祥生医疗产品安全性与质量体系全面 接轨国际最高标准。 祥生医疗相关 ...

盛夏时节，在临港区各大项目施工现场，塔吊林立、机器轰鸣，一个个项目以"满格"状态全速推进，处处涌动着建设热潮，为全区高质量发展注入澎湃动 力。 企业当"红娘" 眼下，海维电子科技（威海）正在抢抓施工"黄金期"，以最快速度开展项目建设，引进2台DZ20KW/10MEV直线电子加速器、1台DD2MEV/100KW高频高 压型电子加速器等设备，准备年内完成项目建设和设备调试，将其建成国内首屈一指的辐照中心。 三产融合"补短板" 项目施工现场热火朝天。 记者 刘鹏雪 摄 位于临港区的威海赛威医疗科技有限公司，是一家从事医用一次性体外诊断产品研发、生产和销售的现代化高新技术企业，生产的产品需要进行辐照消 毒。项目落地之前，公司的产品工业辐照环节全部在上海鑫海维科技有限公司的分基地完成，每天的运输成本都在上千元。 "要不要在临港区新建一个辐照中心？"这样的想法在双方心中逐渐成型。于是，经赛威医疗"牵线搭桥"，上海鑫海维科技有限公司同临港区商务局取得联 系，双方一拍即合。经过多次地块考察，最终，海维电子科技（威海）有限公司成功落户临港区。 "我们在临港区有几十家客户，通过考察发现，这里的区位优势对我们开拓新市场有非常大的意 ...

Group 1 - The core viewpoint is that Mingde Biological has experienced significant growth in market capitalization and development in the POCT rapid diagnostic field since its listing, but its operational performance has shown notable fluctuations in recent years [1][3]. - Mingde Biological's main business includes the independent research, production, and sales of POCT rapid diagnostic reagents and testing instruments, with in vitro diagnostic products and solutions accounting for the highest revenue share at 62.89% [3]. - The company achieved a cumulative profit growth of 21.33% from a net profit of 0.61 billion yuan in 2018 to 0.75 billion yuan in 2024, with no annual losses recorded since its listing [3]. Group 2 - Revenue analysis shows that Mingde Biological's revenue peaked at 9.59 billion yuan in 2020 but fell to 3.50 billion yuan in 2024, indicating a significant decline post-pandemic [3]. - Profit analysis reveals that the net profit reached a high of 4.69 billion yuan in 2020, dropping to 0.75 billion yuan in 2024, reflecting a substantial adjustment after the pandemic peak [3]. - Since its listing, Mingde Biological's market capitalization has increased by 142%, peaking at 150.45 billion yuan in May 2022, but has since decreased by 68.47% to 47.43 billion yuan as of July 2023 [5].

Core Viewpoint - The financial performance of Shanghai RunDa Medical Technology Co., Ltd. in 2024 showed a significant decline in revenue and net profit compared to previous years, primarily due to fixed costs not decreasing in line with revenue drops and the impact of industry-wide pricing pressures [1][11]. Financial Performance - The company reported a revenue of 8.312 billion yuan in 2024, a year-on-year decrease of 9.13% [1][11]. - The net profit attributable to shareholders was 55.2806 million yuan, down 79.77% year-on-year, significantly higher than the industry average decline [1][11]. - The commercial segment generated 7.864 billion yuan in revenue, a decrease of 8.34%, with a gross margin of 23.27%, down 1.27 percentage points [1][6]. - The industrial segment reported 442 million yuan in revenue, down 21.18%, but with a gross margin of 62.12%, up 5.22 percentage points [1][8]. Cost Structure - The company’s operating costs, including service costs, depreciation, and other fixed expenses, did not decrease proportionately with the revenue decline, leading to pressure on profit margins [11][12]. - Sales expenses decreased by 8.01% to 840.78 million yuan, while management expenses decreased by 5.67% to 479.94 million yuan [11][12]. - Financial expenses remained relatively stable, with a slight decrease of 1.03% to 313.44 million yuan [11][12]. Segment Analysis - The commercial segment includes traditional supply chain services, centralized/regional testing center services, and third-party laboratory services, with varying gross margins [4][6]. - The gross margin for traditional supply chain services was 25.83%, down from 26.41% in 2023, while the third-party laboratory services saw a significant drop from 40.70% to 33.30% [6][8]. - The industrial segment's gross margin increased due to the exclusion of lower-margin quality control products from the consolidated financials [8][12]. Industry Comparison - The company’s gross margins in the commercial segment are competitive with industry peers, with no significant differences noted [6][8]. - The overall trend in the industry shows a decline in revenue and profit margins due to macroeconomic factors and healthcare cost control policies [14][15]. Future Outlook - The company is expected to continue facing challenges from pricing pressures and the need to manage fixed costs effectively to improve profitability [11][12]. - There is a focus on enhancing operational efficiency and exploring new revenue streams to mitigate the impact of declining margins [12][15].

Group 1 - The core business of the company focuses on high-margin medical consumables and equipment, specifically medical imaging products and in vitro diagnostic products [2] - The company has established a strong sales network in China and has gained the trust of international manufacturers such as Fujifilm, Roche Diagnostics, Becton Dickinson, and Thermo Fisher Scientific [2] - The company is the exclusive manufacturer of medical film for Fujifilm in China and one of the largest distributors of Roche's in vitro diagnostic products in the country [2] Group 2 - As of July 2, the company's stock price increased by 11.5% to HKD 0.126 per share, with a trading volume of 16.97 million shares and a turnover of HKD 2.21 million [1] - The company has achieved a cumulative increase of 26.97% in the past month and 82.26% year-to-date, outperforming the Hang Seng Index's 20% increase [1] - Financial data shows that for the year ending December 31, 2024, the company reported total revenue of CNY 2.41 billion, a year-on-year decrease of 17.26%, while net profit attributable to shareholders was CNY 922 million, a year-on-year increase of 6736.05% [1]

Group 1 - The number of IPOs in Hong Kong has significantly increased in the first half of 2025, with A-share companies also increasingly announcing plans to list in Hong Kong [1] - In Q2 2025, the Hong Kong Stock Exchange (HKEX) surpassed NASDAQ in terms of fundraising scale, achieving a net fundraising amount of HKD 1,067.13 billion, a year-on-year increase of 688.56% [2][3] - Despite having fewer IPOs than NASDAQ in Q2 (27 vs. 83), the fundraising amount from Hong Kong IPOs reached HKD 880.44 billion, exceeding NASDAQ's USD 9.5 billion (approximately HKD 744.94 billion) [3] Group 2 - The number of Chinese companies listing in the US has increased, with 40 companies going public in the first half of 2025, up from 25 in the same period last year. However, the total fundraising amount decreased by 59.73% to USD 7.45 billion [4] - The largest fundraising in A-shares during the first half of 2025 was from Zhongce Rubber, which raised RMB 39.33 billion, followed by Tianyouwei and Yingshi Innovation [5] - The largest IPO in the US was from Venture Global, raising USD 1.67 billion, while the largest in Hong Kong was CATL, raising HKD 353.31 billion (approximately USD 45.01 billion) [7] Group 3 - The best-performing new stocks in A-shares this year include Jiangnan New Materials with a cumulative increase of 419.29%, followed by Haibosichuang and Tianhe Magnetic Materials [8] - In the US market, the top-performing new stocks include Diginex with a cumulative increase of 584.00%, followed by Anbio and CoreWeave [8] - In Hong Kong, the best-performing new stock is Gu Ming, with a cumulative increase of 158.06% [8] Group 4 - The number of companies queued for IPOs in Hong Kong for the second half of 2025 has significantly increased, with at least 8 companies confirmed to list in July and August [9] - From June 27 to June 30, 23 companies submitted applications for the first time on the HKEX, including several A-share companies [9] - The influx of new listings may lead to differentiated performance based on the flow of funds and the quality of the companies, emphasizing the importance of fundamental analysis over speculative trading [9]

Core Viewpoint - Compliance is essential for the sustainable development of enterprises, and AnTu Bio has integrated compliance into every aspect of its operations, from R&D to financial management [1][2]. Group 1: Compliance Management - AnTu Bio emphasizes compliance training for new employees, incorporating real business scenarios to instill a compliance mindset [2]. - The management team includes compliance decision-making in daily operations, holding monthly simulations to embed compliance responsibilities across all processes [2]. - Supplier compliance management is viewed as a key driver for high-quality development in the industry, with strict standards for supplier qualification and tax credit reviews [2]. Group 2: Tax Policies and R&D Investment - Recent tax reduction policies have provided financial support for enterprises to increase R&D investments, with AnTu Bio investing over 10% of its annual revenue in R&D for the past three years [3]. - AnTu Bio is set to launch 144 new products, including magnetic microparticle chemiluminescence and molecular diagnostics, in 2024 due to its sustained high R&D investment [3]. Group 3: Tax and Compliance Collaboration - The tax authority in Zhengzhou has included AnTu Bio in its "Chief Tax Officer" service list, providing tailored support and monitoring the company's operational status [4]. - A proactive approach to tax management has led to a significant cash flow relief for AnTu Bio, with a recent identification of 2.73 million yuan in incremental tax credits [4]. - AnTu Bio's strong tax credit rating has resulted in a 125.10% increase in bank credit limits since 2020 and a reduction in financing costs by 0.86 percentage points, saving over 8.65 million yuan in financial expenses in 2024 [4].